Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas

Walter A. Hall, Nancy Doolittle, Megan Daman, Patti K. Bruns, Leslie Muldoon, David Fortin, Edward Neuwelt

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The prognosis for patients with diffuse pontine gliomas (DPG) remains poor. New aggressive innovative treatments are necessary to treat this disease. From 1984 to 1998, eight patients (4M/4F), median age 11 years, with DPG were treated with monthly osmotic blood-brain barrier disruption (BBBD) chemotherapy using intraarterial carboplatin or methotrexate and intravenous cytoxan and etoposide. Patients presented for a median duration of 6 weeks with increased intracranial pressure, long tract signs, diplopia, ataxia, and nausea/vomiting. DPG was demonstrated on magnetic resonance (MR) imaging in seven patients and on CT in one. Two patients had biopsies that showed an astrocytoma and an anaplastic astrocytoma. Three tumors enhanced on MR imaging after contrast administration. Three patients had radiation therapy before BBBD chemotherapy and four afterwards. Two patients had chemotherapy (tamoxifen, topotecan) before BBBD chemotherapy and two afterwards. In general, patients were evaluated with MR imaging every 3 months to monitor for a response to treatment. The median number of chemotherapy cycles that were administered by BBBD was 10, mean 10. Three patients also received one, two, or three cycles of intraarterial chemotherapy without BBBD. One patient that was started on carboplatin was converted to methotrexate, and five that were started on the methotrexate protocol were later converted over to carboplatin. One patient received monthly methotrexate followed by 14 days of procarbazine and one patient started on methotrexate was switched to navelbine. MR imaging demonstrated two partial responses, five patients with stable disease, and one with disease progression. The median time to tumor progression was 15 months with the range from

Original languageEnglish (US)
Pages (from-to)279-284
Number of pages6
JournalJournal of Neuro-Oncology
Volume77
Issue number3
DOIs
StatePublished - May 2006

Fingerprint

Blood-Brain Barrier
Glioma
Drug Therapy
Methotrexate
Carboplatin
Magnetic Resonance Imaging
Astrocytoma
Procarbazine
Topotecan
Diplopia
Intracranial Pressure
Etoposide
Ataxia
Tamoxifen
Cyclophosphamide
Nausea
Vomiting
Disease Progression
Neoplasms
Radiotherapy

Keywords

  • Blood-brain barrier
  • Brainstem glioma
  • Midbrain
  • Pontine glioma

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. / Hall, Walter A.; Doolittle, Nancy; Daman, Megan; Bruns, Patti K.; Muldoon, Leslie; Fortin, David; Neuwelt, Edward.

In: Journal of Neuro-Oncology, Vol. 77, No. 3, 05.2006, p. 279-284.

Research output: Contribution to journalArticle

Hall, Walter A. ; Doolittle, Nancy ; Daman, Megan ; Bruns, Patti K. ; Muldoon, Leslie ; Fortin, David ; Neuwelt, Edward. / Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas. In: Journal of Neuro-Oncology. 2006 ; Vol. 77, No. 3. pp. 279-284.
@article{13ad5922d3cc42c6a39aa854fee46fb0,
title = "Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas",
abstract = "The prognosis for patients with diffuse pontine gliomas (DPG) remains poor. New aggressive innovative treatments are necessary to treat this disease. From 1984 to 1998, eight patients (4M/4F), median age 11 years, with DPG were treated with monthly osmotic blood-brain barrier disruption (BBBD) chemotherapy using intraarterial carboplatin or methotrexate and intravenous cytoxan and etoposide. Patients presented for a median duration of 6 weeks with increased intracranial pressure, long tract signs, diplopia, ataxia, and nausea/vomiting. DPG was demonstrated on magnetic resonance (MR) imaging in seven patients and on CT in one. Two patients had biopsies that showed an astrocytoma and an anaplastic astrocytoma. Three tumors enhanced on MR imaging after contrast administration. Three patients had radiation therapy before BBBD chemotherapy and four afterwards. Two patients had chemotherapy (tamoxifen, topotecan) before BBBD chemotherapy and two afterwards. In general, patients were evaluated with MR imaging every 3 months to monitor for a response to treatment. The median number of chemotherapy cycles that were administered by BBBD was 10, mean 10. Three patients also received one, two, or three cycles of intraarterial chemotherapy without BBBD. One patient that was started on carboplatin was converted to methotrexate, and five that were started on the methotrexate protocol were later converted over to carboplatin. One patient received monthly methotrexate followed by 14 days of procarbazine and one patient started on methotrexate was switched to navelbine. MR imaging demonstrated two partial responses, five patients with stable disease, and one with disease progression. The median time to tumor progression was 15 months with the range from",
keywords = "Blood-brain barrier, Brainstem glioma, Midbrain, Pontine glioma",
author = "Hall, {Walter A.} and Nancy Doolittle and Megan Daman and Bruns, {Patti K.} and Leslie Muldoon and David Fortin and Edward Neuwelt",
year = "2006",
month = "5",
doi = "10.1007/s11060-005-9038-4",
language = "English (US)",
volume = "77",
pages = "279--284",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Osmotic blood-brain barrier disruption chemotherapy for diffuse pontine gliomas

AU - Hall, Walter A.

AU - Doolittle, Nancy

AU - Daman, Megan

AU - Bruns, Patti K.

AU - Muldoon, Leslie

AU - Fortin, David

AU - Neuwelt, Edward

PY - 2006/5

Y1 - 2006/5

N2 - The prognosis for patients with diffuse pontine gliomas (DPG) remains poor. New aggressive innovative treatments are necessary to treat this disease. From 1984 to 1998, eight patients (4M/4F), median age 11 years, with DPG were treated with monthly osmotic blood-brain barrier disruption (BBBD) chemotherapy using intraarterial carboplatin or methotrexate and intravenous cytoxan and etoposide. Patients presented for a median duration of 6 weeks with increased intracranial pressure, long tract signs, diplopia, ataxia, and nausea/vomiting. DPG was demonstrated on magnetic resonance (MR) imaging in seven patients and on CT in one. Two patients had biopsies that showed an astrocytoma and an anaplastic astrocytoma. Three tumors enhanced on MR imaging after contrast administration. Three patients had radiation therapy before BBBD chemotherapy and four afterwards. Two patients had chemotherapy (tamoxifen, topotecan) before BBBD chemotherapy and two afterwards. In general, patients were evaluated with MR imaging every 3 months to monitor for a response to treatment. The median number of chemotherapy cycles that were administered by BBBD was 10, mean 10. Three patients also received one, two, or three cycles of intraarterial chemotherapy without BBBD. One patient that was started on carboplatin was converted to methotrexate, and five that were started on the methotrexate protocol were later converted over to carboplatin. One patient received monthly methotrexate followed by 14 days of procarbazine and one patient started on methotrexate was switched to navelbine. MR imaging demonstrated two partial responses, five patients with stable disease, and one with disease progression. The median time to tumor progression was 15 months with the range from

AB - The prognosis for patients with diffuse pontine gliomas (DPG) remains poor. New aggressive innovative treatments are necessary to treat this disease. From 1984 to 1998, eight patients (4M/4F), median age 11 years, with DPG were treated with monthly osmotic blood-brain barrier disruption (BBBD) chemotherapy using intraarterial carboplatin or methotrexate and intravenous cytoxan and etoposide. Patients presented for a median duration of 6 weeks with increased intracranial pressure, long tract signs, diplopia, ataxia, and nausea/vomiting. DPG was demonstrated on magnetic resonance (MR) imaging in seven patients and on CT in one. Two patients had biopsies that showed an astrocytoma and an anaplastic astrocytoma. Three tumors enhanced on MR imaging after contrast administration. Three patients had radiation therapy before BBBD chemotherapy and four afterwards. Two patients had chemotherapy (tamoxifen, topotecan) before BBBD chemotherapy and two afterwards. In general, patients were evaluated with MR imaging every 3 months to monitor for a response to treatment. The median number of chemotherapy cycles that were administered by BBBD was 10, mean 10. Three patients also received one, two, or three cycles of intraarterial chemotherapy without BBBD. One patient that was started on carboplatin was converted to methotrexate, and five that were started on the methotrexate protocol were later converted over to carboplatin. One patient received monthly methotrexate followed by 14 days of procarbazine and one patient started on methotrexate was switched to navelbine. MR imaging demonstrated two partial responses, five patients with stable disease, and one with disease progression. The median time to tumor progression was 15 months with the range from

KW - Blood-brain barrier

KW - Brainstem glioma

KW - Midbrain

KW - Pontine glioma

UR - http://www.scopus.com/inward/record.url?scp=33748422851&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748422851&partnerID=8YFLogxK

U2 - 10.1007/s11060-005-9038-4

DO - 10.1007/s11060-005-9038-4

M3 - Article

VL - 77

SP - 279

EP - 284

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -